By Ria Kakkad (Drug Target Review)2023-01-20T15:38:55
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-03-03T14:06:14
Sponsored by Bio-Techne
2024-01-26T13:22:42
Sponsored by bit.bio
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2023-07-04T10:05:58
Sponsored by Revvity
2026-03-25T15:00:00 2026-03-25T16:00:00
Sponsored by Yokogawa
2024-05-07T13:11:19
Sponsored by BellBrook Labs
Site powered by Webvision Cloud